Sanofi Targets Larger Deals After Strong Q3 Results
Sanofi plans larger acquisitions to rebuild its drug pipeline under CEO Belen Garijo. The French drugmaker also raised its 2026 growth targets after reporting stronger than expected third-quarter sales.
Xurve View
Insights:
Xurve View
Sanofi lifted its 2026 growth targets and signaled plans to pursue larger acquisitions during morning trade on Friday. The France-based drugmaker aims to replenish its drug pipeline following trial setbacks. The strategy shift seeks to accelerate top-line expansion and boost late-stage development assets.
